Re: Pharmacogenomic variation of CYP2D6 and the choice of optimal adjuvant endocrine therapy for postmenopausal breast cancer: A modeling analysis

被引：0
|
作者：
Gurwitz, David [1 ]
Newman, William [2 ]
机构：
[1] Tel Aviv Univ, Dept Human Mol Genet & Biochem, Sackler Fac Med, IL-69978 Tel Aviv, Israel
[2] Univ Manchester, Dept Med Genet, Manchester M13 9PL, Lancs, England
来源：
JOURNAL OF THE NATIONAL CANCER INSTITUTE | 2008年 / 100卷 / 18期
关键词：
D O I：
10.1093/jnci/djn269
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Genetic polymorphisms of CYP2D6 increase the risk for recurrence of breast cancer in patients receiving tamoxifen as an adjuvant therapy
    Solai Elango Damodaran
    Suresh Chandra Pradhan
    Gurusamy Umamaheswaran
    Dharanipragada Kadambari
    K. Sathyanarayana Reddy
    Chandrasekaran Adithan
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 75 - 81
  • [32] CYP2D6 polymorphisms influence the efficacy of adjuvant tamoxifen in Thai breast cancer patients
    Sirachainan, Ekaphop
    Jaruhathai, Sureerat
    Trachu, Narumol
    Panvichian, Ravat
    Sirisinha, Thitiya
    Ativitavas, Touch
    Ratanatharathorn, Vorachai
    Chamnanphon, Montri
    Sukasem, Chonlaphat
    PHARMACOGENOMICS & PERSONALIZED MEDICINE, 2012, 5 : 149 - 153
  • [33] CYP2D6 and ESR genotypes in adjuvant tamoxifen treatment for early breast cancer.
    Kim, K.
    Jung, K. H.
    Ahn, J.
    Kim, S.
    Kim, H. J.
    Ko, B.
    Lee, J. W.
    Son, B. H.
    Ahn, S.
    Gong, G.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (27)
  • [34] CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy
    Sophie E. Mayer
    Noel S. Weiss
    Jessica Chubak
    David R. Doody
    Christopher S. Carlson
    Karen W. Makar
    Michelle A. Wurscher
    Kathleen E. Malone
    Cancer Causes & Control, 2019, 30 : 103 - 112
  • [35] CYP2D6-inhibiting medication use and inherited CYP2D6 variation in relation to adverse breast cancer outcomes after tamoxifen therapy
    Mayer, Sophie E.
    Weiss, Noel S.
    Chubak, Jessica
    Doody, David R.
    Carlson, Christopher S.
    Makar, Karen W.
    Wurscher, Michelle A.
    Malone, Kathleen E.
    CANCER CAUSES & CONTROL, 2019, 30 (01) : 103 - 112
  • [36] The effect of CYP2D6*10 polymorphism on adjuvant tamoxifen in Asian breast cancer patients: a meta-analysis
    Lu, Junjun
    Li, He
    Guo, Peng
    Shen, Rui
    Luo, Yingbin
    Ge, Qiao
    Shi, Wenfei
    Li, Yan
    Zhu, Weikang
    ONCOTARGETS AND THERAPY, 2017, 10 : 5429 - 5437
  • [37] CYP2D6 genotype affects outcome in postmenopausal breast cancer patients treated with tamoxifen monotherapy
    Thompson, A. M.
    Bray, S.
    Johnson, A. M.
    Quinlan, P.
    Nikloff, D. M.
    Evans, D. G.
    Clarke, R.
    Lawrence, H. J.
    Howell, A.
    Latif, A.
    Ferraldeschl, R.
    Hillman, G.
    Fontecha, M.
    Newman, W. G.
    BREAST CANCER RESEARCH, 2010, 12 : S15 - S15
  • [38] Association between CYP2D6 genotypes and the clinical outcomes of adjuvant tamoxifen for breast cancer: a meta-analysis
    Jung, Jin-A
    Lim, Hyeong-Seok
    PHARMACOGENOMICS, 2014, 15 (01) : 49 - 60
  • [39] CYP2D6 genotypes in Spanish women with breast cancer
    Ladona, MG
    Abildua, RE
    Ladero, JM
    Roman, JM
    Plaza, MA
    Agundez, JAG
    Munoz, JJ
    Benitez, J
    CANCER LETTERS, 1996, 99 (01) : 23 - 28
  • [40] CYP2D6 Genotyping and the Use of Tamoxifen in Breast Cancer
    Berry, Donald
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2013, 105 (17): : 1267 - 1269
12345